All News

Technology, COVID-19, and scope expansion—here’s how pharmacists can capitalize on opportunities coming in the new year.

Serotypes 22F, 33F, and 3 represent more than a quarter of invasive pneumococcal disease in children under the age of 5

Offering individual advice and counseling to patients can help combat the risks of driving under the influence of prescription drugs.

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

Emicizumab-kxwh demonstrated a favorable safety profile and effective bleed control in people with mild or moderate hemophilia A without factor VIII inhibitors.

The study demonstrates a need for novel tolerable and efficacious therapeutic agents to address the burden of illness in patients with multiple myeloma, according to the investigators.

The study examined safety, immune response (immunogenicity), and adverse effects of 7 vaccines when used as a third booster jab.

The data presented shows that at 16 weeks, individuals who added the atopic dermatitis drug to low potency standard-of-care topical corticosteroids experienced 28% achieved clear or almost-clear skin.

Dermoplast offers short-term relief of pain and itching from certain skin conditions, such as sunburn, scrapes, and insect bites.

Gabapentin enacarbil treats moderate-to-severe primary restless leg syndrome and postherpetic neuralgia.

GERD is mild acid reflux that occurs at least twice a week or moderate to severe acid reflux that occurs at least once a week.

Study results show that clonal hematopoiesis of indeterminate potential is associated with a lower likelihood of developing AD.

Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections

Data support daratumumab as part of a standard of care regimen in the frontline setting for patients with newly diagnosed multiple myeloma.

Results from a study show that elderly individuals who are black or who have an immediate family member with a current or past blood cancer have higher rates of these conditions.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .

The investigators said this increase in risk is particularly pronounced in those with more advanced disease.

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Overall, approximately 41% of those receiving Axi-cel and 16% of those receiving standard of care survived for 2 years without needing additional cancer treatment or experiencing cancer progression.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.

The standard-of-care for patients with LBCL consists of chemotherapy and additional high intensity chemotherapy followed by stem cell transplantation.

CAR T-cell therapy shows durable long-term survival in patients with refractory LBCL, company’s Kite subsidiary says.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.

The investigators analyzed an existing data set from the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies, which included surveys on diet and exercise from a diverse patient population at 12 hospital centers across the United States.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how iFCR therapy increases the chance of functional cure for younger individuals with chronic lymphocytic leukemia.

Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.